What is TAP?
TAP is a strategic venture philanthropy funding initiative to accelerate high-risk, innovative blood cancer therapeutics and change the standard of care in leukemia, lymphoma, and multiple myeloma.
Since its establishment in 2007, TAP has invested more than $120 million in over 60 projects.
How can TAP benefit your company?
Listen to what the Chief Medical Officer of Forty Seven, Chris Takimoto, has to say about TAP and the value created for his company.
Recently Forty Seven was acquired by Gilead Sciences for $4.9 Billion.
Since 2017, three TAP-supported therapies have been approved by the U.S. Food and Drug Administration (FDA):
CPX-351 (Vyxeos®), first approved treatment (an innovative reformulation of two chemotherapies) for patients with certain types of high-risk acute myeloid leukemia (AML) - approved on August 3 2017 with clinical data published in Journal of Clinical Oncology
Axicabtagene ciloleucel (Yescarta®), first CAR T-cell immunotherapy approved for patients with non-Hodgkin lymphoma (NHL) and transformed follicular lymphoma (tFL) - approved on October 18 2017 with clinical data published in Lancet Oncology
Tagraxofusp-erzs (Elzonris®), first approved therapy for children and adults with blastic plasmacytoid dendritic cell neoplasm (BPDCN) - approved on August 3 2017 with clinical data published in New England Journal of Medicine
Currently, there are over 20 TAP-supported companies or institutions with assets in active development, including 5 ongoing or planned registration-enabling clinical studies.
“We are honored and delighted to be partnering with LLS to advance what we see as truly innovative therapeutics with the potential to transform cancer treatment for patients. This collaboration will further our research efforts and ensure patients have access to clinical studies and the latest information on our approach and medicines.”
- Jared Gollob, M.D., Chief Medical Officer, Kymera Therapeutics
View archived TAP webcasts and programs
- Value Creation for Companies: Dollars & Beyond (Coming Soon)
- LLS Research Now: LLS’s Venture Philanthropy Model for Accelerating Promising Therapies (Archived October 2020)
- LLS Business Networking Reception ASH 2019 (Archived December 2019)
“LLS’s selection of mavorixafor for TAP collaboration and investment reinforces its potential as a novel therapy for Waldenström’s macroglobulinemia. Approximately 30 to 40 percent of WM patients have a CXCR4 mutation, and a number of these patients do not respond well to current therapies. We look forward to working closely with Dr. Greenberger [LLS CSO] and the LLS TAP team to gain valuable data and insights throughout the upcoming clinical trial as we work to bring a new therapeutic option to patients with this rare form of cancer.”